BaşcıSAtaNAltıntaşF, et al.Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors. J Oncol Pharm Practice2020. DOI: 10.1177/1078155220953198
2.
HochhausALarsonRAGuilhotF, IRIS Investigatorset al.
Long-Term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med2017;
376: 917–927.
3.
DyallJColemanCMHartBJ, et al.Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother2014;
58: 4885–4893.
4.
SiskJMFriemanMBMachamerCE.Coronavirus S protein-induced fusion is blocked prior to hemifusion by ABL kinase inhibitors. J Gen Virol2018;
99: 619–630.
5.
BrecciaMAbruzzeseEBocchiaM, Campus CML working groupet al.
Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey. Leukemia2020;
34: 2260–2261.
